A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

  • Diffuse Large B-Cell Lymphoma
  • Chronic Lymphocytic Leukemia
Trial Status:

Completed

This trial runs in
Countries
  • Australia
  • United States
Trial Identifier:

NCT01991184 GO29089

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This open-label, Phase I study will evaluate the safety, tolerability, and pharmacokinetics of increasing doses of GDC-0853 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia. In a dose-expansion part, GDC-0853 will be assessed in subsets of patients.

      Genentech, Inc. Sponsor
      Phase 1 Phase
      NCT01991184 , GO29089 Trial Identifier
      GDC-0853 Treatments
      Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma Condition
      Official Title

      An Open-Label, Phase I, Dose-Escalation Study Evaluating The Safety And Tolerability Of Gdc-0853 In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Age >/= 18 years
      • ECOG score of 0-1
      • One of the following histologically-documented hematologic malignancies for which no effective standard therapy exists: indolent non Hodgkin's lymphoma (NHL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL)
      • At least one site of disease that, as seen on CT scan, is > 1.5 cm in the greatest transverse diameter or > 1.0 cm in short axis diameter (except for patients with CLL)
      • An available tumor specimen
      • Adequate hematologic and organ function
      • For female patients of childbearing potential and male patients with partners of childbearing potential, use of effective contraceptive(s) as defined by protocol for the duration of the study
      Exclusion Criteria
      • Life expectancy < 12 weeks
      • < 3 weeks since the last anti-tumor therapy, including chemotherapy, biologic, experimental, hormonal or radiotherapy (with the exception of leuprolide or similar medications for prostate cancer)
      • Recent major surgical procedure or traumatic injury, or unhealed incisions or wounds
      • Active infection requiring IV antibiotics
      • Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis.
      • Primary CNS malignancy or untreated/active CNS metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control)
      • History of other malignancy within 5 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin cancer, Stage I uterine cancer, or other cancers with a similar outcome
      • Cardiovascular dysfunction, including ventricular dysrhythmias or risk factors for ventricular dysrhythmias
      • Pregnancy, or lactation
      • Any other diseases that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now